Miguel Angel Samaniego-Laguna

Medical Student in Mexico | Strong interest in cardiology and surgery | Open to research | ☕️🏋🏻 are the key

[Hemostasis Today @HemostasisToday]

Extending Impella 5.5 Support Beyond 14 Days in Cardiogenic Shock - Tooba Rehman

https://t.co/V23eRcF8tp

#Hematology #Hemostasis #HemostasisNews #HemostasisToday #Medicine #Health #MedX #MedNews #MedEd

[CardiovascularCorner @TrackYourHeart]

Visualization of atherosclerotic plaque formation leading to rupture, clotting cascade & platelet aggregation, resulting in total thrombus occlusion of an artery.

[Miguel Angel Samaniego-Laguna @MiguelSama1007]

New publication alert 🫀🔪

Our new meta-analysis in @JCVAonline shows that intraoperative hemoadsorption during cardiac surgery with CPB reduces the risk of #AKI, but does not improve mortality, RRT use, or length of stay.

Link here: https://t.co/PWZ7SPGqBU

[JAMA @JAMA_current]

📊 Research Summary: Adults with #AFib who drank at least one cup of caffeinated coffee daily after successful cardioversion had a lower risk of recurrence than those who abstained from coffee and caffeine.

#AHA25

https://t.co/CoGRhvpUbZ

[Miguel Angel Samaniego-Laguna @MiguelSama1007]

New publication!

patients with HFrEF treated with CMA (OM & danicamtiv).

•No significant effect on mortality
•Modest reduction in composite CV outcomes & stroke risk.

Read more: 10.1016/j.hrtlng.2025.10.015

#HeartFailure #Cardiology #Research #MetaAnalysis

[Ahmed Bennis MD 🫀 @drbennisahmed]

Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA

Obstructive or extensive nonobstructive CAD by CCTA identifies overweight/obese individuals without diabetes and no prior CVD as being at elevated cardiovascular risk, suggesting potential benefit from glucagon-like peptide-1 receptor agonist therapy

@JACCJournals @ACCinTouch @DrMarthaGulati @hvanspall @dranulala @CMichaelGibson @ankeetbhatt @AndrewJSauer @Hragy @AnastasiaSMihai

https://t.co/HV5JKUqVBJ

[Miguel Angel Samaniego-Laguna @MiguelSama1007]

Honored to present our work on heart failure at ACC Latin America 2025.
A great experience of learning, networking, and growth with colleagues and leaders in cardiology.
Thanks to @ACCinTouch for making it possible!

[EJPC Editor-in-Chief @EJPCEiC]

📌Baseline nitric oxide (NO) metabolite profile is unfavourable in patients with HF and lower VO2peak or higher NT-proBNP
🚫No significant influence of HIIT or MCT on NO metabolites at 3 and 12 months
https://t.co/6xp2y72dfL
@escardio @AboyansV @SilCastelletti @PeroneFrancesco

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM

🥸 I am not sure the association here is strong - could statistical chance: interpret with caution; here you go: #ESCCongress2025

👇👇👇

[Miguel Angel Samaniego-Laguna @MiguelSama1007]

Excited to announce that I will be presenting my research at #ACCLatinAmerica2025 🇲🇽

“Efficacy of CMAs vs Placebo in Patients with HFrEF: A Systematic Review and Meta-Analysis of RCTs”

👉 See you in Mexico City, September 18–20.
#CardioResearch #HeartFailure #ACC

[Ahmed Bennis MD 🫀 @drbennisahmed]

Cardiovascular-Kidney-Metabolic Syndrome: A Paradigm for Value-Based Care

The financial burden is staggering, with CKM-related conditions driving $900 billion in annual direct health care costs, a figure set to rise as the prevalence of diabetes, hypertension, obesity, and chronic kidney disease (CKD) increases.

@mvaduganathan @ankeetbhatt @gcfmd @AndrewJSauer @DrMarthaGulati @BiykemB @hvanspall @iamritu @hfcollaboratory @CMichaelGibson

https://t.co/Xks8Sc0rOy

[Gonzalo Perez @gonzaeperez]

DROGAS ANTIARRITMICAS
Consenso EHRA 👌🏿
Vía @ESC_Journals

https://t.co/bGMxHEDbbK

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis: AGENT IDE Subgroup Analysis: @JACCJournals

🥸 on drug coated balloons.

👇👇👇

[American College of Cardiology @ACCinTouch]

SOGALDI-PEF: In pts w/ HFmrEF/#HFpEF, the combination of dapagliflozin plus spironolactone led to a greater reduction in NT-proBNP levels than dapagliflozin alone, indicating improved cardiac stress.

Learn more: 🔗 https://t.co/tjhEdyeXp1 #JACC @JACCJournals

[Ankeet S. Bhatt, MD, MBA, ScM @ankeetbhatt]

#HFimpEF is common, but data are limited on #GDMT & outcomes. In @JACCJournals, the largest look at HFimpEF in US to date.
🎯>28K new HFrEF pts, 1 in 3 improved to HFimpEF.
🎯 GDMT ⤵️ after HFimpEF.
🎯 Many pts remained at ⏫ risk.

💡 Tailored trials & #ImpSci strategies needed.

[EJPC Editor-in-Chief @EJPCEiC]

🧬 Does high #Lp(a) accelerate #coronarycalcification?
⬇️ This study finds no significant link between elevated Lp(a) levels and the development or progression of coronary artery calcification.

https://t.co/GqXJxeK172

[Evangelos K. Oikonomou @ekoikonomou]

We know AI-ECG and AI-Echo can detect transthyretin amyloid cardiomyopathy (ATTR-CM), but:

– How early can they pick up the phenotype?
– Can we track its progression with digital biomarkers?

Find out in our @cards_lab study in @ehj_ed
Thread below 🧵👇

w/ @rohan_khera @Sadeer_AlKindi + a stellar team of collaborators #EHJ #CardioTwitter

[Miguel Angel Samaniego-Laguna @MiguelSama1007]

Read the full study in Cureus: https://t.co/VEoi2cU8uv

[Miguel Angel Samaniego-Laguna @MiguelSama1007]

New Publication Alert!
Landiolol for heart rate control in patients with sepsis or septic shock.
📉 Landiolol significantly reduced HR
⚠️ Increased the risk of hypotension
💀 No clear mortality benefit observed
#CriticalCare #Sepsis #Tachycardia #MedTwitter #ICU #MetaAnalysis

[Miguel Angel Samaniego-Laguna @MiguelSama1007]

Excited for my first abstract as first author has been accepted for oral presentation at ACC Latin America 2025!
Deeply grateful to my mentors, co-authors, and everyone who supported me.
@metaacademy_ofc @ACCinTouch @ACC_Mex #ACC25 #HeartFailure #EvidenceBasedMedicine